All In MedTech

Device Trial Radar · NCT03530306

Treatment Evaluation of Neuromodulation for Tinnitus - Stage A2

Treatment Evaluation of Neuromodulation for Tinnitus - Stage A2 (TENT-A2)

Last checked: Nov 20, 2026Latest source record: Dec 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 191 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

191

Actual

Start

Mar 20, 2018

Primary completion

Oct 2, 2018

Study completion Jul 18, 2019

Sponsor

Lead sponsor
Neuromod Devices Ltd.Not on our public-company list
Sponsor type
Industry
First posted
May 21, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a four arm, patient subtyping and parameter optimisation study for a neuromodulation treatment for tinnitus.

Conditions

  • Tinnitus

Interventions

  • PS1-PS4Device

    Participants in this arm shall be given PS1 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.

  • PS6-PS10Device

    Participants in this arm shall be given PS6 during the first half of treatment and PS10 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.

  • PS7-PS4Device

    Participants in this arm shall be given PS7 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.

  • PS9-PS6Device

    Participants in this arm shall be given PS9 during the first half of treatment and PS6 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tinnitus Handicap Inventory (THI)Time frame: Between-arm and within-arm changes in THI after 6 weeks of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • St. James's Wellness Trust Clinical Research Facility

    Dublin, Ireland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.